Wegovy and Acetaminophen Interaction: What Patients Need to Know

The two drugs, briefly

Wegovy contains semaglutide 2.4 mg, a glucagon-like peptide-1 (GLP-1) receptor agonist administered by subcutaneous injection once weekly and approved by the FDA for chronic weight management. Although Wegovy shares its active ingredient with Ozempic (semaglutide at lower doses for type 2 diabetes) and Rybelsus (oral semaglutide), differences in formulation, dosing strength, and clinical indication mean that drug interactions observed with one version cannot be assumed to apply to another without supporting evidence.

Acetaminophen (paracetamol) is an over-the-counter and prescription-combination analgesic and antipyretic. It is metabolized in the liver and is also, separately, one of the most commonly used pharmacokinetic "probe drugs" that researchers use to measure how fast a person's stomach empties, because its absorption depends heavily on gastric transit time rather than on liver enzyme activity (Willems et al., 2001).

What actually happens when the two are taken together

GLP-1 receptor agonists slow gastric emptying as part of how they reduce appetite and food intake. Because acetaminophen is absorbed almost entirely in the small intestine, anything that keeps it in the stomach longer will delay how quickly its blood level rises, even if the total amount eventually absorbed does not change much. This is the mechanism the Wegovy prescribing information describes when discussing concomitant oral medications (FDA label, Wegovy), and it is consistent with what is known generally about GLP-1 receptor agonists and gastric motility (Marathe et al., 2013).

A related, better-documented data point comes from a study of semaglutide 1 mg in adults with obesity, which used the acetaminophen absorption test directly to quantify gastric emptying and found that acetaminophen exposure in the first hour after dosing was reduced, with absorption catching up by five hours (Hjerpsted et al., 2018). This is the strongest single piece of published evidence behind the "delayed but not lost" description of the interaction, and it is worth naming because it is a dedicated pharmacokinetic study rather than a label summary.

The core, quotable answer with its boundary: Wegovy's FDA label describes a pharmacokinetic interaction in which semaglutide delays acetaminophen's time to peak concentration and lowers its peak level, without a clinically meaningful change in total absorption; this data comes from a dedicated interaction study conducted at the 1 mg semaglutide dose, not the 2.4 mg Wegovy maintenance dose, and the FDA has not required a dose adjustment for acetaminophen. Readers who need the exact percentage figures for a clinical decision should confirm them against the current label text rather than relying on secondhand summaries, including this one.

What the FDA label does, and does not, establish

The Wegovy label addresses concomitant oral medication use in its drug interactions section and states, in substance, that semaglutide's gastric emptying effect has the potential to affect absorption of oral drugs taken at the same time (FDA label). The underlying clinical pharmacology review, a separate FDA document, contains the numeric drug-interaction data that summaries of this topic (including earlier versions of this page) have quoted as a roughly 20 to 25 percent reduction in acetaminophen Cmax and a delay in Tmax of about an hour (FDA Clinical Pharmacology Review).

Two things matter here and are easy to lose in a quick read. First, the interaction study behind these numbers used semaglutide 1 mg, the dose approved for type 2 diabetes under a different brand, not the 2.4 mg dose that defines Wegovy. The FDA's decision not to require a dose adjustment reflects a judgment that the effect generalizes across the semaglutide dose range, not a study conducted at 2.4 mg itself. Second, the FDA did not issue a boxed warning, contraindication, or acetaminophen dose change for this pairing. Both of these are label-level facts; the specific percentages attached to them should be checked line by line before being repeated as exact figures in a clinical conversation.

An earlier version of this article attributed a specific quotation about attenuation of gastric emptying effects over time to Dr. Jens Juul Holst. That quotation could not be verified against the cited source, a general physiology review of GLP-1 (Holst, 2007), and has been removed. What can be said, generally and without attributing a specific sentence to a specific person, is that gastric emptying delay from GLP-1 receptor agonists is often most pronounced early in treatment and may lessen somewhat with continued use; this is a plausible, class-level pattern rather than a precisely quantified finding tied to acetaminophen specifically.

Evidence-status interaction assessment: Wegovy and acetaminophen

Liver safety: what is and is not shown

Acetaminophen is metabolized mainly through glucuronidation and sulfation, with a smaller fraction converted by CYP2E1 into the reactive metabolite NAPQI, which is normally neutralized by glutathione (Mazaleuskaya et al., 2015). Toxicity is a function of total dose and glutathione reserve, not of gastric emptying speed; the FDA's general guidance for adults without liver disease is no more than 3,000 mg per day from all sources combined, a figure to confirm on the current FDA acetaminophen information page since dosing guidance can be updated (FDA acetaminophen information).

Semaglutide is cleared by proteolytic cleavage and fatty-acid side-chain oxidation rather than by cytochrome P450 enzymes, so there is no established shared metabolic pathway between the two drugs (FDA label). The STEP 1 trial of semaglutide 2.4 mg for weight management reported liver enzyme changes as part of its metabolic outcome data, with a signal toward improvement rather than harm (Wilding et al., 2021); the exact effect size for ALT reduction should be checked against the published trial report and its supplement before it is used as a specific number, since that level of detail is often confined to supplementary material rather than the primary abstract. This is trial evidence about semaglutide's effect on liver enzymes in general, not evidence about acetaminophen co-administration specifically, and the two should not be conflated into a claim that Wegovy "protects" against acetaminophen's liver risk.

Patients with pre-existing liver disease or regular heavy alcohol use have reduced glutathione reserves and are more vulnerable to acetaminophen-related injury regardless of what else they are taking; many clinicians advise a lower personal ceiling (often cited around 2,000 mg per day) for this group, and that recommendation should come from the treating clinician rather than a general guidance page.

Practical timing guidance

No dose adjustment to acetaminophen is indicated for patients on Wegovy. For occasional use, standard adult dosing (commonly 500 to 1,000 mg every four to six hours, not exceeding the daily maximum from all sources) applies; because the FDA-reported data describe a delayed and somewhat lower peak, relief may begin a bit later than a patient is used to, particularly early in Wegovy treatment. Anyone using acetaminophen for time-sensitive relief, such as before a scheduled procedure, may want to build in extra lead time and discuss this with the prescribing or supervising clinician rather than self-adjusting the dose.

For scheduled, regular acetaminophen use, such as for chronic osteoarthritis pain, the delayed single-dose peak matters less because steady-state levels depend on the overall dosing interval rather than any single peak, and the FDA-reported AUC data suggest total exposure at steady state should not meaningfully change.

Patients should track acetaminophen from every source, not just standalone tablets. Hundreds of prescription and over-the-counter products, including opioid-acetaminophen combinations and multi-symptom cold and flu remedies, contain acetaminophen, and the FDA has flagged this as a source of accidental overdose across the general population (FDA acetaminophen information; Blieden et al., 2014).

Other oral drugs affected by the same mechanism

Semaglutide's gastric emptying effect is not specific to acetaminophen; it applies, to varying degrees, to oral medications generally, and the FDA label describes dedicated interaction studies for several of them (FDA label; FDA Clinical Pharmacology Review):

• Combined oral contraceptives (ethinyl estradiol/levonorgestrel): a dedicated study found reduced Cmax for both components without a clinically relevant AUC change, and the study authors concluded backup contraception was not needed on that basis (Kapitza et al., 2015).
• Atorvastatin: reported Cmax reduction with AUC largely preserved; statin efficacy tracks more closely with total exposure over time than with peak level, so this is generally not considered clinically significant, though exact figures should be confirmed against the current label.
• Digoxin: a narrow-therapeutic-index drug where the label reports PK changes; because digoxin toxicity and under-treatment both carry real risk, checking serum levels around the time semaglutide is started or the dose is escalated is a reasonable, individualized clinical judgment rather than a blanket requirement.
• Warfarin: the label reports warfarin exposure changes within standard bioequivalence bounds, meaning no clinically relevant PK interaction was demonstrated. Any recommendation to check INR more often during semaglutide initiation should come from the prescribing clinician's own judgment about that patient's anticoagulation stability, since the guideline previously cited for this specific point did not, on verification, address GLP-1 co-administration.
• Metformin: no clinically significant interaction is described, consistent with metformin's absorption site and profile.

Because the gastric emptying effect persists throughout the weekly semaglutide dosing interval, separating an oral medication from the day of the Wegovy injection does not avoid the interaction.

When to contact a prescriber or seek urgent care

Reach out to a prescriber, or seek urgent evaluation, for:

• Signs of possible liver injury: yellowing of skin or eyes, dark urine, severe right upper abdominal pain, or unexplained fatigue. These warrant prompt evaluation regardless of what is causing them.
• Persistent nausea or vomiting that prevents keeping any oral medication down, which is a known side effect during Wegovy dose escalation and can affect absorption of any oral drug independent of the gastric-emptying interaction discussed here.
• Use of a narrow-therapeutic-index medication such as warfarin, digoxin, phenytoin, or levothyroxine alongside Wegovy, where even modest absorption changes may be more clinically consequential and individualized monitoring decisions should involve the prescribing clinician.
• Regular acetaminophen use above 2,000 mg per day combined with heavy alcohol use, low body weight, or known liver disease, where individualized dosing advice from a clinician is appropriate rather than general guidance.

Evidence boundary

What is established: semaglutide delays gastric emptying, and this is expected, mechanistically, to delay acetaminophen's absorption; the FDA label documents an interaction study consistent with that direction of effect and does not recommend an acetaminophen dose change; acetaminophen and semaglutide are cleared through different, non-overlapping metabolic pathways.

What is plausible but not rigorously demonstrated: that the delay meaningfully slows a patient's perceived onset of pain relief in everyday use, and that the gastric-emptying effect is more pronounced early in treatment and lessens with continued dosing.

What is not established from the sources available for this page: the exact percentage change in Cmax and Tmax at the 2.4 mg Wegovy dose specifically (the underlying study used 1 mg); any specific liver-society endorsement of GLP-1 therapy to offset acetaminophen risk; and any cardiology- or endocrine-society-specific recommendation to intensify monitoring of warfarin, digoxin, or similar drugs during Wegovy initiation. These points should be confirmed against current primary sources before being used in patient counseling.